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Abstract Health economic aspects have been increas-
ingly important during introduction of new treatments for
multiple sclerosis. As a partial response for Norway, a cost-
of-illness study was carried out to estimate the yearly cost
of the illness to society and relate costs and patients’
quality of life to illness severity. Estimated cost to society
was Euro 439 million in 2002 exclusive of the cost of
reduced quality of life. The cost per patient was close to
Euro 65,000. Account taken of methodological differences,
the results compare to results for Sweden, Norway’s closest
neighboring country. The illness reduced patients’ quality
of life with 0.26. More patients were early retired because
of their MS in Norway than in any of nine other European
countries comprised by a recent European study, illustrat-
ing a liberal practice in Norway. The Norwegian cost of
unpaid assistance was almost identical to the Swedish cost
that was the lowest found across the countries in the
European study. When related to illness severity, the cost
per patient increased, and the patients’ experienced quality
of life decreased with increasing EDSS levels in line with
what has been found for other countries. Cost-of-MS
studies have been carried out for a number of countries.
Together they contribute to our understanding of the eco-
nomic consequences of multiple sclerosis and, if their
results are related to illness severity, also provide valuable
information for further economic analyses of treatment and
medication. Our study adds to this.
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Introduction
Multiple sclerosis (MS) is a complex, chronic inflamma-
tory disease of the central nervous system, characterized by
demyelination and axonal loss resulting in the accumula-
tion of neurological functional impairment and disability.
The progressive loss of function results in a high level of
disability [1, 2], and it has long been recognized that the
illness brings high costs upon both patients and society
[3–5]. During the 1990s, immunomodulatory drugs were
introduced. The treatment does not cure the illness, but
may delay disease progression and reduce at least some
costs related to disease activity and progression [6, 7]. The
medication is costly, the effect modest and health author-
ities are increasingly considering economics in the intro-
duction of such treatments.
Objective
The objective of this work was to estimate of the cost of
MS to the Norwegian society and the per-patient costs and
patients’ quality of life related to illness severity.
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Method
Cost-of-illness analyses are prevalence- or incidence-based
or a combination. Prevalence-based studies give the cost of
all cases in a given, usually one-year, time period. Inci-
dence-based studies give an estimation of life-time costs
for patients contracting the illness during a given time
period. We used the prevalence approach, estimating
the total cost of the illness during 2002. All costs to the
Norwegian society were included irrespectively of who
paid, and opportunity costs exclusive of taxes or subsidies
were applied. Collection of data was ‘‘top–down’’, using
aggregate figures related to diagnoses codes from available
databases, national statistics and registries, and ‘‘bottom
up’’ collecting information directly for a limited sample of
patients. Only costs caused by the patients’ MS were
included, not all costs of patients with MS. Bottom–up
information on resource use, work participation and quality
of life was collected through a postal questionnaire survey
among MS patients in Hordaland County, Western
Norway.
We used an adapted version of a questionnaire that had
been used in the earlier studies of MS in Europe [8, 9] to
minimize problems for the patients to understand and
answer the questionnaire correctly. The questionnaire was
focused on the current situation the preceding month of
data collection, except for questions on adaptations and
special equipment that are typically provided to MS
patients only once or a few times during their illness where
a one-year recall period was used. Patients were explicitly
asked to include only aspects related to multiple sclerosis.
Quality-of-life (QoL) data were collected using a generic,
preference-based instrument, the EQ-5D questionnaire [10]
that was incorporated in our questionnaire.
All returned questionnaires were reviewed by the first
author. Inconsistent or illogical answers were corrected
where possible or else considered unanswered. A maxi-
mum number of 12 h of daily assistance from family and
friends was allowed for. In cases where volume lacked for
indicated resource use or reduced work participation,
average volumes for the answering patients were used. All
answers were entered into an Excel sheet for summation
and calculation of averages. All entries were double-
checked by the first author. Selected information was
transferred to SPSS (Statistical Package for Social Sci-
ences) for further analysis.
Bottom–up information on illness severity, expressed by
scoring of the Kurtzke Expanded Disability Status Scale
(EDSS) [11], was collected from medical records at Hau-
keland University Hospital, Hordaland County. EDSS is
the most commonly used disability status scale in MS
research and includes eight functioning systems: Pyramidal
function, cerebellar function, brainstem function, sensory
function, bladder/bowel function, visual function and
mental function. To measure impairment, we used a ten-
point scale that divides EDSS between points 1 and 10
(10 = dead due to MS). The medical records from all MS
patients were scrutinized for clinical information within
1 year by an experienced clinical neurologist.
Top–down information on resource use and work par-
ticipation was collected from national registries etc. where
relevant information could be extracted based on diagnoses
codes or otherwise. In cases where extraction was not made
by routine, we met with the registries to discuss how
information could be extracted to best fit our needs and
then placed an order for the information.
For unit costs of resource use, we would ideally have
used market prices, normally reflecting the cost to society
directly. In Norway, most health services are, wholly or
partly, paid for by the State and pure market prices may
seldom be found. Instead, maximum prices that the pro-
viders are allowed to charge for their services if the State
is to pay their specified part of the price are negotiated
between the Norwegian health authorities and the health
service providers’ organizations. As these prices are
accepted by the providers, they must be assumed to cover
the full cost of the services including profit/cost of capital
and therefore also reflect cost to society. As an alternative
to using market prices, we therefore chose to use price or
tariff lists that expressed these negotiated amounts as unit
costs. For unit costs of changes in work participation,
national statistics on the cost of labor was used. This
contains all elements of the payment for labor and
therefore reflects costs to society of utilizing the labor
force.
For maximum coverage of costs, no relevant cost item
was excluded from the study on a` priori assumptions that it
would be of a so modest magnitude that the cost of
checking it further would not be reflected in a corre-
sponding increase in the value of the study’s results [12].
Extrapolation of costs to society
A recent epidemiological survey showed a prevalence of
about 150 per 100,000 population in Hordaland County
[13]. Other recent updates of MS epidemiology in Norway
have indicated prevalence at 150–160 per 100,000 popu-
lation in the counties of Nord-Trøndelag and Oslo [14].
The prevalence in the three northernmost counties is usu-
ally considered to be somewhat lower, and for estimation
of the total Norwegian MS population, we used a preva-
lence of 100/100,000 for the three northernmost counties
and 150/100,000 for counties further south. In line with
this, we based our extrapolation of the information from
the postal survey among MS patients in Hordaland County
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on the assumption of a similar MS population throughout
Norway of a total of 6,750 patients.
Material
Top–down information on resource use and work partici-
pation was collected from four sources: the National
Insurance Administration, the Norwegian Patient Registry,
Statistics Norway and statistics from the pharmaceutical
product producers.
• The National Insurance Administration manages dis-
ability pensions and sickness benefit in Norway and
pays for occupational rehabilitation and technical aids.
• The Norwegian Patient Registry contains information
on all patients waiting for or having received specialist
health services in Norway.
• Statistics Norway is the central body responsible for
covering the need for statistics on the Norwegian
society.
• Pharmaceutical product producers keep track of drug
sales in Norway.
Bottom–up information on resource use, work partici-
pation and quality of life was collected through the postal
survey in Hordaland County. Five hundred and sixty-five
patients with a definite MS diagnosis according to the
Poser criteria [15] were registered in Hordaland County. In
collaboration with the local MS Society, 526 (93%) of the
patients were found available for the postal survey. The
rest was considered unavailable either because their current
postal address was unknown or due to fear that they might
react negatively to be addressed as ‘‘MS patients’’ for the
purpose of a survey. Of the 526 patients who were mailed a
questionnaire, 423 (80%) responded. The questionnaire
was structured into 7 different components, demographic
and clinical information, drug use, ambulatory care, insti-
tutionalization, support and assistance, work participation
and quality of life, and provided a broad set of information.
Not only information that could not be gathered from the
national-level sources described above, but also informa-
tion that was also collected from those sources. This pro-
vided us with two sets of information on some important
elements of resource use and work participation. Medical
records at Haukeland University Hospital provided infor-
mation on patient demographics, diagnoses, illness dura-
tion and disability.
Five price or tariff lists expressing negotiated amounts
assumed to reflect unit costs to society were found:
• ‘‘The standard tariff for physicians in private practice’’,
‘‘Directions for benefits covering expenses to investi-
gation and treatment by psychologists’’ and ‘‘Tariff for
treatment by physiotherapists’’ contain the negotiated
maximum prices physicians in private practice, psy-
chologists and physiotherapists are allowed to charge
for their services.
• ‘‘Tariff for services provided by physicians in hospi-
tals’’ contains the maximum amounts hospitals are
allowed to charge directly to patients. The amounts are
assumed to cover approximately 50% of the hospitals’
total costs of providing the services and must be
multiplied by a factor of two to reflect relevant costs to
society.
• ‘‘The Norwegian Pharmaceutical Product Compen-
dium’’ contains maximum allowed prices for drugs sold
in Norway. Norwegian health authorities set the rules
for the pricing and these are accepted by the producers.
In addition to information from these sources, infor-
mation on unit costs was also collected from ‘‘Samdata’’
and Statistics Norway.
• ‘‘Samdata’’ is an organizational unit, established to
produce effective management control information for
Norwegian hospitals. Part of this information is average
full costs at Norwegian hospitals for different stays.
These average full costs must be assumed to reflect the
costs to society of the stays reasonably well.
• Statistics Norway’s labor cost statistics reflect the
prices of labor in Norway as set by the market.
The study was approved by the Norwegian Regional
Committee for Medical Research Ethics and the Norwe-
gian Data Inspectorate.
Information use
In line with the considerations above on input information
availability, we used the sales figures for interferon b and
glatiramer acetate from the producers’ sales statistics as our
estimate of the cost to society of the use of these drugs in
MS treatment. The drugs were not used for other purposes.
For other prescription drugs, information on use was taken
from the postal survey and on unit costs from the Norwe-
gian Pharmaceutical Product Compendium. Average costs
per month were calculated based on average unit price and
recommended dose. In the case of over-the-counter drugs
and complementary and alternative medication where no
standard value components were available, patients’ infor-
mation on monetary outlays from the survey was used.
Information on the utilization of ambulatory care was
taken from the postal survey and on unit costs from the
negotiated price-/tariff lists for services provided by phy-
sicians, psychologists and physiotherapists. For services
provided by physicians in hospitals, the listed amounts
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were multiplied by a factor of two. Price or tariff lists for
services provided by other professionals were not avail-
able, and their unit costs were assumed identical to phys-
iotherapy cost, except for the cost of visits to or by nurses
were information on nurses’ salaries, typical health-sector
overhead costs and duration of visits were used. Trans-
portation costs were added for all home visits.
Institutionalization of MS patients includes three forms,
stays at hospitals, nursing homes and rehabilitation centers.
The hospital stays are either overnight stays denoted ‘‘bed-
days’’ or stays only during daytime, denoted ‘‘day-stays’’ in
this study. Information on the number of bed-days and day-
stays in hospitals was collected both through the postal
survey in Hordaland County and the Norwegian Patient
Registry. The information from the postal survey indicated
a total number of bed-days and day-stays 50% higher than
what was recorded at the patient registry. A comparison of
the answers to the postal survey with information from
medical records at Haukeland University Hospital revealed
that approximately 15% of the days in hospitals reported by
the patients through the survey were for earlier periods than
the preceding month of data collection. This may explain
slightly less than 50% of the difference in the number of
days reported by the patients and the patient registry. In
addition, investigation by the Norwegian Patient Registry
had previously revealed that the coding in reports from the
hospitals to the registry on diagnoses and medical proce-
dures had been inaccurate. Errors were found in as much as
200 out of a random sample of 500 reports, and our own
check of medical records at Haukeland University Hospital
indicated specifically that also some MS-related stays had
not been reported correctly. Given this uncertainty in the
information from both sources, we chose our estimates
mid-way between the information from the two sources.
The practical consequences of possible mistakes in this
choice are limited since days in hospitals counted for less
than 10% of the days in hospitals, nursing homes and
rehabilitation centers altogether. The unit cost of MS
patients’ bed-days in hospitals was estimated from infor-
mation from Samdata. Corresponding information on the
cost of day-stays was not available, and the unit cost of
day-stays was assumed to be one-third of the cost of bed-
days. We assumed MS-caused stays in nursing homes and
rehabilitation centers to be bed-days only, and information
on their numbers was taken from the postal survey. No
specific information on the unit costs of these stays was
found. We based our estimates on information given by
managers of such institutions that was reasonably consis-
tent with information in a prospect on the building and
running of new institutions.
Collecting information on the cost to the Norwegian
society of adaptations for and special equipment to MS
patients posed special problems. Much of the equipment
and adaptations are long lasting and typically provided to
patients only once, or a few times. This makes information
on the volumes of the equipment and adaptations gathered
through a prevalence-based questionnaire to a limited
sample, especially uncertain. Further, the equipment and
adaptations are often tailor-made with no general market
price or unit cost. Ideally, the needed information should
have been collected from the National Insurance Admin-
istration that has general responsibility to provide all
Norwegian citizens with health-related needs for technical
aids and buys these from commercial actors. If the pur-
chases to MS patients could have been singled out, the total
amount would have been pretty close to the total cost to
society of equipment and adaptations due to MS. As for
today, the National Insurance Administration’s purchases
are not recorded according to diagnoses, so singling out the
relevant entities was not possible. Neither could the
insurance administration help in providing the average
costs for relevant categories of equipment, as ‘‘electric
wheelchairs’’, ‘‘adaptations of cars’’ etc. We had to rely on
less satisfactory sources. Information on volumes was
taken from the survey, where patients were asked to supply
information on the number of units they had received the
last year within assumed relevant categories of equipment
and adaptations. We also made an attempt to collect the
information through an incidence-based approach where
persons with assumed expert knowledge were asked to
estimate the life-time needs of adaptations and equipment
of an average MS patient. The response was close to nil,
the non-responders arguing that the question could not be
answered realistically. Information on unit costs were
sought from suppliers and compared to stipulated unit costs
within the same categories of equipment and adaptations in
the Swedish study from 2001. For most of the equipment
and adaptations, we found that a reasonable estimate of
Norwegian (NOK)-unit costs might be the SEK costs in the
Swedish study multiplied by a factor of 1.5. In one
instance, adaptations of cars, we assumed that the adapta-
tions contained more than was assumed for the Swedish
study and our cost estimate was more than 6 times higher.
For ‘‘other adaptation of houses’’, the opposite was the case
and our NOK estimate was slightly lower than the Swedish
SEK estimate. In a few instances, the content of the cate-
gories used in the two studies varied somewhat. This was
only for equipment that from a cost perspective was
unimportant, however. Information on MS patients use of
paid assistance was taken from the postal survey and on
unit costs from Statistics Norway’s labor cost statistics for
the actual occupational groups.
The cost to society of on non-paid assistance to MS
patients by relatives and friends at times when the pro-
viders would alternatively have performed paid work was
estimated using the human capital method. Volume
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information arrived from the postal survey. Unit costs were
taken from Statistics Norway’s labor cost statistics. This
information from statistics Norway showed that women
perform fewer hours of paid work and have lower salaries
than men. For our study, we assumed that these differences
were not caused by differences in productivity, but by
women performing more unpaid work at home. To arrive at
our estimates of the unit costs, we therefore chose Statistics
Norway ‘s labor costs (gross salary including employers’
contribution) for men as unit cost of help provided also by
women. Assistance at times the providers alternatively
would have used for leisure activities was valued at
employees’ salary net of tax, reflecting the providers
opportunity cost of this assistance.
Also the cost to society of patients’ reduced work par-
ticipation was calculated using the human capital method.
Information on reduced participation in paid work for the
patients in the form of short- and long-term sick leaves,
early retirement and reduced posts was available from the
National Insurance Administration and the postal survey.
The information from the National Insurance Administra-
tion indicated 30–40% more work-days lost because of sick
leave due to MS than the information from the survey; 40%
of the responders to the postal survey did not answer the
questions on sick leave. These were assumed not to have
had sick leave, and this may have resulted in some under-
statement of the volume of sick leaves in the information
from the survey. Further, the information from the National
Insurance Administration was on compensation for lost
income for absences from work and had to be adjusted to be
comparable to the information from the postal survey. This
may have added extra uncertainty, and there were also
uncertainties due to coding practices. We used our best
judgment to choose our estimate somewhat closer to the
information from the National Insurance Administration.
As for hospitalization, the practical consequences of pos-
sible mistakes in this choice is limited since the cost of sick
leaves only contributed with slightly more than 10% of the
total cost of sick leaves, rehabilitation stays and reduced
posts/early retirement altogether. To arrive at the number of
work-years lost due to reduced posts and early retirement,
we used information from the survey. The information was
consistent with corresponding information from the insur-
ance administration. For unit costs, gross salary for men
including employers’ contribution was used.
Information on premature deaths was available from
Statistics Norway. Consistent with our prevalence approach,
the number of work-years lost due to MS-caused premature
deaths was estimated from Statistics Norway’s ‘‘Causes of
death’’ statistics by extracting the persons that in 2002 would
have been alive at less than pension age if they had not died
of MS earlier. Gross salary for men was used as estimate of
unit cost to society.
Patients’ answers to the EQ-5D questionnaire were,
consistent with general EuroQol recommendations [16],
translated into utilities via a value set originally developed
with the instrument from an UK population as no com-
prehensive value set for Norway existed. When negative
utility values occurred, these were put to zero. The number
of quality-adjusted life-years (life-years at full health/QA-
LYs) lost due to MS was estimated by calculating the
difference in utility between the MS sample in our study
and an age-matched general population sample [17] of
same size.
The information on patients’ EDSS levels from the
medical records was used for two purposes. First to relate
resource use, reductions in work participation and quality
of life to illness severity for the group of patients
responding to the postal survey and second to assign costs
and quality-of-life information to non-responding and non-
available patients for calculation of averages for the total
MS population in Hordaland County. Of the 526 patients
who were mailed a questionnaire, 423 (80%) responded.
Information on the patients in the non-available and non-
responding groups in the records was comparable to the
responding group what age at diagnosis, gender and disease
course was concerned. For the non-responding patients,
also the EDSS levels compared. For the non-available
patients, the average EDSS level was somewhat lower, 3.5
versus 4.3 for the responding and non-responding groups.
Average costs for the responders at each EDSS level were
assigned to the non-responding and non-available patients
at corresponding EDSS levels.
The cost of a relapse was estimated to account for two
times the difference in average monthly costs between
patients at EDSS levels less than 6 with and without
relapse, assuming an average relapse lasting 2 months and
that relapses are seldom and difficult to identify at higher
EDSS levels than 5.5. In addition, we estimated the effect
of relapses on patients’ quality of life by comparing quality
of life in patients at EDSS levels less than 6 experiencing a
relapse to that of patients on the same EDSS levels without
relapse.
Results
Patient demographics
Out of 565 registered MS patients with a definite MS
diagnosis in Hordaland County, 526 were considered
available for a postal survey and 423 responded. The mean
age at diagnosis was 37.7 (±10.6) years, and mean EDSS-
level was 4.3 (±2.1). 65.1% was women; 25.5% indicated
that they had a relapsing–remitting MS (RRMS) and 52.1%
a primary or secondary progressive disease (PPMS/SPMS)
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while the rest were either uncertain or did not answer this
question. Clinical and demographic data are summarized in
Table 1.
Direct economic cost
Drug cost was € 30.1 million (Table 2). During 2002, the
proportion of patients that used immunomodulatory treat-
ment in Norway was approximately 25% and the cost was
€ 25.3 million. A total of 37% of the patients had bought
other prescribed or over-the-counter drugs and 24% com-
plimentary or alternative medication the preceding month
of data collection.
The cost of ambulatory care was € 24.0 million
(Table 2). Nearly 20% of the patients had received
ambulatory care by a neurologist the month preceding data
collection and slightly more than 20% by their general
practitioner. Approximately 11% had received home ser-
vice by a nurse and close to 40% physiotherapy. Most
patients had also received treatment from other profes-
sionals, such as occupational therapists, opticians, chirop-
odists and acupuncturists. The main cost was related to
nurse home visits (including transportation costs) to the
most disabled patients. Treatment by physiotherapists
constituted the second largest cost item.
The cost of institutionalization was € 44.4 million
(Table 4). The proportion of patients that reported they had
been hospitalized (bed-days) the preceding month of data
collection was 2.8%. Also 2.8% received rehabilitation and
4.0% were at nursing homes. Even with some uncertainties
in the information on hospital stays, the major cost ele-
ments were related to stays at rehabilitation centers and
nursing homes due to longer stays.
The cost of adaptations, equipment and assistance was
€ 72.9 million (Table 4). Adaptations in the home had
been done during the last year in 11.3% of the patients,
and 6.1% had received adaptation or support for their car.
The major equipment costs were related to electric
wheelchairs and adaptation of cars. We divided assistance
into paid and unpaid assistance. The major costs of paid
assistance were related to personal assistant, home care
services and child care. The cost of unpaid assistance was
related to sick leave or reduced posts for relatives, as well
as spare time used by relatives and friends to help
patients. Patients’ transport cost was negative due to
reduced travel to work.
Indirect economic cost
Patients’ MS-related reduced participation in paid work
was due to short-term sick leave because of acute disease
activity or long-term sick leave due to disease progression,
stays at rehabilitation centers, reduced posts, early retire-
ment and premature death. The major cost components
were due to early retirement and reduced posts (Table 3).
Fifty percent of the responders were fully retired due to
their MS. Fourteen percent had reduced posts. For these,
the average reduction in work load was 51.5%.
Quality of life
Measured with the EQ-5D questionnaire using the UK
value set, the patients reported a mean reduction in quality
of life of 0.427. The reduction due to MS was 0.260. When
measured with the EQ VAS, the reductions in quality of
life were lower, mainly due to some patients at EDSS 6 and
higher reporting considerably higher quality of life on the
EQ VAS than what was calculated using the EQ-5D
questionnaire (Table 6). The mean total reduction as
measured by the EQ VAS was 0.372 and the reduction due
to MS 0.205.
Cost to society
Adding the direct and indirect economic costs showed an
estimated total cost of MS to the Norwegian society of €
Table 1 Clinical and demographics of the responding MS patients
(n = 423)
Characteristics Proportion or mean (±SD)
Gender
Male 34.9%
Female 65.1%
Mean age at diagnosisa 37.7 (±10.6) years
Type of MSa
Relapsing–remitting MS (RRMS) 25.5%
Progressive MS (PPMS/SPMS) 52.1%
Unknown 22.4%
Disability levelb
Mean EDSS level 4.3 (±2.1)
Median EDSS level 4.0
EDSS score 0–3 43.5%
EDSS score 4–6.5 43.0%
EDSS score 7–9 13.5%
Relapse during last montha
Yes 11.8%
No 76.2%
Unknown 12.0%
Employment
Yes 33.7%
No 65.5%
Unknown 0.8
a Self-reported
b Hospital records
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439 million during 2002 (Table 4). Direct economic costs
accounted for 39% and indirect economic costs for 61%.
According to the postal survey, 14.3% of the patients at
EDSS-levels 5.5 or lower had experienced a relapse the
preceding month of data collection. QoL was reduced with
0.16 among the patients experiencing a relapse compared
to those without relapse. Assuming a relapse lasts for
2 months on average, a relapse was estimated to cost €
5,170 (Table 5).
Analyses of costs and quality of life related to illness
severity showed increasing MS-related costs and reduced
quality of life along with increasing disability (Table 6) in
line with what have been found for other countries [18].
Direct economic costs related to treatment and care of MS
patients were more than 7 times higher at EDSS-levels 7–8
compared to levels 1–2, and indirect economic costs due to
patients’ reduced participation in paid work were more
than 2 times higher. The relatively modest increase in
indirect economic costs is mainly explained by a large part
of the patients at EDSS-levels 1–2 having reduced posts, in
addition to some also being fully retired already at these
low levels of illness severity.
Table 2 Estimates of the annual (2002) cost of drug use and ambulatory care due to MS
Drugs Doses Unit cost (€) Annual cost (1,000 €)
Immunomodulatory drugs interferon beta/glatiramer acetate NA NA 25,266.3
Relapse treatment (methylprednisolone, prednisolone) 1,346 111.6 150.2
Other prescription or over-the-counter drugs NA NA 3,699.0
Complimentary or alternative medicine NA NA 1,019.9
Drug total 30,135.4
Ambulatory care Consultations/treatments Annual cost (1,000 €)
Physicians 2024.2
Physicians in private practice
General practitioners 17,801 45.8 815.3
Specialists 3,777 43.4 163.9
Home visits 2,160 102.8 222.0
Contact by telephone etc. 7,554 4.7 35.5
Physicians in hospitals 9,686 81.3 87.5
Nurses 13,896.1
At office 11,331 22.6 256.1
Home visits 318,263 42.6 13,558.0
Contact by telephone etc. 10,789 7.6 82.0
Other professionals 8,041.5
Psychologists 3,777 51.4 194.1
Physiotherapists 156,434 39.9 6,241.7
Occupational therapists 7,554 39.9 301.4
Incontinence advisors 1,075 39.9 42.9
Speech therapists 1,075 39.9 42.9
Social welfare workers 542 39.9 21.6
Social workers 2,160 39.9 86.2
Opticians 5,394 39.9 215.2
Chiropodist 7,554 39.9 301.4
Acupuncturists 8,958 39.9 357.4
Homeopaths 1,617 39.9 64.5
Chiropractors 542 39.9 21.6
Healers 1,075 39.9 42.9
Sone therapists 542 39.9 21.6
Various other professionals 2,160 39.9 86.2
Ambulatory care total 581,820 23,961.8
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Discussion
The objective of this study has been to estimate the total
annual cost of MS to the Norwegian society and the per-
patient costs and patients’ quality of life related to illness
severity. Our estimate of the cost to society for 2002 was €
439 and per patient € 65,037. Our approach was prevalence
based, giving MS-caused costs during 2002. Prevalence-
based approaches are usually considered suitable for
chronic illnesses like MS. Incidence-based approaches
require the estimation of life-time costs for patients con-
tracting the illness. This is virtually impossible for MS due
to the complexity and long duration of the illness. We used
the human capital method to estimate the cost to society of
all reduced work participation. It has been argued that this
may lead to an overstatement of this cost. First, because
labor costs includes the production of health-related goods
and services [19]. Second because, particularly in times of
high unemployment, a worker might be rapidly replaced
and hence no production loss would occur [20] and third,
especially for premature deaths also because reduced
consumption is not taken into account [21]. These issues
are debated and it is not clear how adjustments might be
done correctly. On balance, we chose, in line with the
choice that has been most typically made also in other cost-
of-MS studies, not to do any such adjustments.
In a study for Sweden [22] Norway’s closest neighbor-
ing country, the cost per patient was estimated to € 53,601
in 2005, 17.6% less than the Norwegian estimate for 2002.
Norwegian price-level increases were marginal from 2002
to 2005, so the nominal amounts should be comparable.
More than half of the difference is due to two methodo-
logical choices, made differently for the studies. The cost
of premature death was included in the Norwegian estimate
but not in the Swedish. This accounts for 37% of the dif-
ference. Further, in the Norwegian study, equal produc-
tivity for both sexes was assumed for the calculation of the
cost of reduced work participation while gender-specific
productivity was used for the Swedish study. This accounts
for another 24%. The remaining difference is caused by a
combination higher costs of patients’ reduced participation
in paid work, institutionalization, ambulatory care and
equipment and adaptations in the Norwegian study, and
lower costs of paid assistance and drugs. The Norwegian
cost of patients’ reduced participation in paid work was
90% higher than in the Swedish study. One-third of this is
due to the cost of MS patients working in reduced posts
being included in the Norwegian study but not in the
Swedish. The remaining difference is mainly due to full-
time early retirement being more than 40% higher in
Norway than in Sweden (51.0/35.7%). It was also higher
than in any other country in a study of 9 European coun-
tries including Sweden [23], illustrating a liberal practice in
Norway. The cost of paid assistance was close to 10 times
higher in Sweden than in Norway almost exclusively due to
much more intensive use of personal assistants. The Nor-
wegian cost of institutionalization exceeded the Swedish
by 21% due to significantly more days in institutions but on
average somewhat lower unit costs, and the Norwegian
Table 3 Estimates of the annual (2002) cost of patients’ reduced
work participation
Patients reduced work
participation due to
Duration Unit
cost
(€)
Annual
cost
(€ 1,000)
Sick leave 27,337.6
Women 76,112 days 236.8 18,023.3
Men 39,334 days 236.8 9,314.3
Rehabilitation 4,468.7
Women 12,404 days 236.8 2,937.3
Men 6,467 days 236.8 1,531.4
Reduced post/early retirement 207,314.1
Women 2,758 years 54,327.6 149,835.5
Men 1,058 years 54,327.6 57,478.6
Premature death due to MSa 524 years 54,327.6 28,467.7
Patients reduced work
participation, total
267,588.1
a Statistics Norway: causes of death
Table 4 Estimate of the 2002 cost of MS to the Norwegian society (€
1,000)
Direct economic cost 171,387
Drugs 30,135
Ambulatory care 23,962
Institutionalization 44,430
Adaptations and equipment 27,754
Paid assistance 11,983
Unpaid assistance 33.123
Indirect economic cost
Patients’ reduced work participation 267,588
Total 438,975
Table 5 Cost of a MS relapse during 2002 (€)
Cost category Patients with
relapse per
month
Patients
without
relapse per
month
Difference 9
2 = cost
of a relapse
Direct economic cost 2,935 1,570 2,730
Indirect economic cost 3,686 2,466 2,440
Total economic cost 6,621 4,036 5,170
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cost of ambulatory care exceeded the Swedish by 18%,
mainly due to more extensive use. The Norwegian drug
cost was 31% lower than the Swedish mainly due to more
use of DMDs in Sweden in 2005 than in Norway in 2002.
Finally, the Norwegian cost of equipment and adaptations
exceeded the Swedish by as much as 300%. It is especially
difficult, however, to get precise information on resource
use and unit costs in this area. The cost of unpaid assistance
in Norway was almost identical to the Swedish cost that
was the lowest found across the nine countries in the
European study.
To provide a complete assessment of the burden of an
illness, intangible costs due to pain, grief, anxiety and
social handicap should theoretically also be included in the
calculations [19]. However, due to difficulties in quanti-
fying these items, they are often excluded from cost-of-
illness studies [22]. In the Swedish study, the costs were
approximated, though, by relating estimated utility losses
to a threshold value for a QALY gained of approximately €
50,000 implied by reimbursement decisions for new
treatments in selected countries [23] and therefore also
assumed to indicate society’s willingness to pay for such
gains [24], indicating an intangible cost of € 11,400 per
patient and year. Applying the same approximation to our
Norwegian data would have resulted in an additional cost
per patient of approximately € 13,000 and € 88 million for
society.
At the outset, we planned to use top–down information
to a largest possible degree, expecting this to be complete
and of high quality. Closer investigation, however,
revealed large uncertainties in the information.
A wide specter of information for our study was gathered
through the postal survey in Hordaland County, and one
potential limitation of this information and our further
extrapolations of it should be noted. The cost effects of the
illness to society for the patients in the MS population in
Hordaland County may not be representative for the cor-
responding cost effects in other parts of Norway. The
Norwegian Multiple Sclerosis Competence centre is located
at the Department of Neurology, Haukeland University
Hospital in Hordaland County, and numerous MS studies
conducted at the department may increase the contact fre-
quency of the patients to the department. However, epide-
miological studies from Hordaland have shown similar
prevalence and patient characteristics of the MS population
compared to other parts of the country [13]. In addition,
national surveys of the use of immunomodulatory treat-
ments have shown that treatment frequency in Hordaland
County has been on the average for the whole county [14].
Hordaland County also comprises both rural and urban
areas like most other counties in Norway and contains
approximately 10% of the MS patients in the country. This
should contribute to make the MS population in Hordaland
County reasonably representative for the national popula-
tion. The possible effect of eventual non-representativeness
of our chosen survey population might therefore be
expected to be modest. For the comparisons with the
Swedish study, it should be noted the average EDSS level
for our sample was 0.8 lower than for the Swedish (4.3/5.1).
This might have reduced the comparability of the results.
Estimates of patients’ EDSS levels are inherently uncertain,
however, and the information was collected differently for
the studies, assessed from medical records for the Norwe-
gian study, and self-reported for the Swedish. For these
reasons, this point has been left out of the discussion.
When we related costs per patient and patients’ quality
of life to illness severity, the per-patient cost increased and
patients’ quality of life decreased with increasing illness
severity in line with what has been found for other coun-
tries when applying the UK value set to our patients’
reported EQ-5D health states. There is not one value set
that is unequivocally ‘‘the best’’ for a given study. Another
value set that might have been relevant for our study could
be a European value set, constructed from data from 11
valuation studies in 6 European countries [16]. Applying
this value set gave quality-of-life values that deviated from
the values calculated from the UK value set with less than
5% for patients up to EDSS-level 5 and with 7% for EDSS-
Table 6 Average quality of life and annual (2002) cost per patient (1,000 €) at categorized EDSS levels (1–9)
Categorized EDSS levels
Quality of life 1 2 3 4 5 6 7 8 9
Generated by the
EQ-5D descriptive system .800 .757 .701 .617 .536 .443 .211 .142 .056
EQ VAS .782 .751 .673 .606 .574 .513 .530 .379 n.a.
Per patient costs
Direct economic cost 7.8 11.4 19.8 24.3 47.9 53.3 50.6 92.4 129.2
Indirect economic cost 22.2 22.1 33.9 37.3 48.7 41.9 45.8 52.1 54.3
Total economic cost 30.0 33.5 53.7 61.6 96.6 95.2 96.4 144.5 183.5
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level 6, but considerably more for EDSS-levels 7, 8 and 9.
The deviations were in both directions. Close to the same
pattern is found if the quality-of-life values calculated from
the UK value set, are compared with the QoL measured by
the EQ VAS, deviations of less than 5% up to EDSS-level
4, deviations of 6 and 16% at EDSS-levels 5 and 6
respectively, and considerably larger deviations for higher
EDSS levels, indicating larger uncertainty in the mea-
surement of quality of life for the most seriously ill MS
patients.
Cost-of-MS-studies have been carried out for a number
of countries. Their results have varied widely, due to
differences in their approach to data collection, the type of
resources included, the valuation of the resources, the type
of patients concerned, the sample process and the quality
of the analysis, in addition to differences between the
countries in absolute and relative prices and healthcare
and social organization [25]. It is hence inappropriate to
directly compare the studies and costs. Still, together they
contribute to increase our understanding of the economic
consequences of multiple sclerosis and, if their results are
related to illness severity, also provide valuable informa-
tion for further economic analyses of treatment and
medication. Our study adds to this. In Norway, interna-
tionally acknowledged guidelines (NICE) are the basis for
admittance and treatment of MS patients. This contributes
to make our findings relevant to other countries. Further,
residents of Norway are universally covered by the wel-
fare system and thus having equal financial access to
diagnostic procedures and health care, giving our study
validity.
Conclusion
We estimated the cost of MS to the Norwegian society to €
439 million in 2002. Per patient cost was close to € 65,000.
The results compare to results from a study in Sweden,
Norway’s closest neighboring country. When costs per
patient and the patients’ quality of life were related to ill-
ness severity, the costs per patient increased and quality of
life decreased with increasing EDSS levels in line with
what has been found for other countries. Studies that relate
per-patient MS costs and patient’s quality of life to illness
severity have been carried out for a number of countries.
They provide valuable information for economic analyses
of treatment and medication. Our study adds to this.
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